Zenas BioPharma (ZBIO) Accounts Payables (2023 - 2026)

Zenas BioPharma's Accounts Payables history runs 4 years deep, the most recent figure standing at $8.9 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 55.32% year-over-year to $8.9 million in Q1 2026; TTM through Mar 2026 was $8.9 million, a 55.32% decrease from a year earlier, with the FY2025 full-year figure at $7.1 million, down 58.5% from the prior year.
• Accounts Payables grew to $8.9 million in Q1 2026 per ZBIO's latest filing, from $7.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $20.0 million in Q1 2025 and bottomed at $5.4 million in Q4 2023.
• The 4-year median for Accounts Payables is $8.4 million (2025), against an average of $11.0 million.
• Across the five-year window, Accounts Payables surged 217.57% in 2024 and sank 58.5% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $5.4 million in 2023, then jumped by 217.57% to $17.1 million in 2024, then tumbled by 58.5% to $7.1 million in 2025, then advanced by 25.78% to $8.9 million in 2026.
• Per Business Quant, the three latest ZBIO Accounts Payables figures stand at $8.9 million (Q1 2026), $7.1 million (Q4 2025), and $6.4 million (Q3 2025).